Hagino, Hiroshi http://orcid.org/0000-0001-8053-1095
Tanaka, Shiro
Kuroda, Tatsuhiko
Mori, Satoshi
Soen, Satoshi
Funding for this research was provided by:
Public Health Research Foundation
Asahi Kasei Pharma Corp.
Article History
Received: 21 March 2024
Accepted: 22 April 2024
First Online: 16 May 2024
Declarations
:
: Dr. Hagino received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Dr. Tanaka has received lecture fees from the Research Institute of Healthcare Data Science. He has received consultation and outsourcing fees from Eli Lilly and Company, Welby, Daiichi Sankyo Company, Limited, Janssen Pharmaceutical K.K., Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health Labour and Welfare, the Japanese Ministry of Education, Science, and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. Dr. Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Dr. Kuroda and Dr. Mori declare no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki and its amendments or comparable ethical standards<b>.</b> Written informed consent was received from participants prior to inclusion in the study.